RecallHawk

JENTADUETO XR (LINAGLIPTIN AND METFORMIN HYDROCHLORIDE)

BOEHRINGER INGELHEIM

Summary

FDA approved JENTADUETO XR (LINAGLIPTIN AND METFORMIN HYDROCHLORIDE) by BOEHRINGER INGELHEIM. NDA (New Drug) approval (Efficacy) on 2023-06-20. TABLET, EXTENDED RELEASE, ORAL.

Details

Source

Drug Approval

External ID

NDA208026-24

Action Date

2023-06-20

Status

Approved

Category

drug

Product Code

NDA (New Drug)

Product Description

JENTADUETO XR (generic: LINAGLIPTIN AND METFORMIN HYDROCHLORIDE), TABLET, EXTENDED RELEASE, ORAL. Application: NDA208026

Context & Analysis

BOEHRINGER INGELHEIM has 10 FDA actions in our database.

Frequently Asked Questions

How often does BOEHRINGER INGELHEIM have FDA actions?

BOEHRINGER INGELHEIM has 10 FDA actions in our database, including 0 recalls and 0 device clearances.

Where can I find the official FDA record?

The official record is available on FDA.gov. Search for "NDA208026-24" on FDA.gov for the full record. You can also use the openFDA API to query this record programmatically.

Want to know the moment something like this happens?

Get alerts for drug

Related Actions